IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ
Overview
Authors
Affiliations
IL-34 is a recently identified cytokine that signals via the M-CSF receptor and promotes monocyte survival. Depending on the environment, monocytes can differentiate into macrophages (Mφ) or dendritic cells (DC). A wide spectrum of Mφ and DC subsets, with distinct phenotypes and functions, has been described. To date, the phenotype of monocytes exposed to IL-34 remains unexplored. We report here that IL-34 induces the differentiation of monocytes into CD14(high) CD163(high) CD1a(-) Mφ (IL-34-Mφ). Upon LPS stimulation, IL-34-Mφ exhibit an IL-10(high) IL-12(low) M2 profile and express low levels of the costimulatory molecules CD80 and CD86. IL-34-Mφ exhibit poor T cell costimulatory properties, and have potent immunosuppressive properties (decrease of TCR-stimulated T cell proliferation). For all the parameters analyzed, IL-34-Mφ are phenotypically and functionally similar to M-CSF-Mφ. IL-34 appears as efficient as M-CSF in inducing the generation of immunosuppressive Mφ. Moreover, the generation of IL-34-Mφ is mediated through the M-CSF receptor, is independent of endogenous M-CSF consumption and is potentiated by IL-6. In an attempt to identify strategies to prevent a deleterious M2 cell accumulation in some pathological situations, we observed that IFNγ and GM-CSF prevent the generation of immunosuppressive Mφ induced by IL-34. IFNγ also switches established IL-34-Mφ into immunostimulatory Mφ. In conclusion, we demonstrate that IL-34 drives the differentiation of monocytes into immunosuppressive M2, in a manner similar to M-CSF, and that IFNγ and GM-CSF prevent this effect.
Leach L, Gonzalez R, Jayawardena S, Gross J bioRxiv. 2025; .
PMID: 39868193 PMC: 11761032. DOI: 10.1101/2025.01.10.632236.
Beielstein A, Izquierdo E, Blakemore S, Nickel N, Michalik M, Chawan S Cell Rep Med. 2024; 5(12):101830.
PMID: 39603243 PMC: 11722127. DOI: 10.1016/j.xcrm.2024.101830.
Liu Z, Hu S, Zhao X, Xu W, Ju F, Gu M J Immunother Cancer. 2024; 12(10).
PMID: 39448199 PMC: 11499773. DOI: 10.1136/jitc-2024-009877.
A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma.
Tang X, Shimada H, Ikegaki N Curr Oncol. 2024; 31(6):3212-3226.
PMID: 38920727 PMC: 11202629. DOI: 10.3390/curroncol31060243.
Innate immune cellular therapeutics in transplantation.
Ott L, Cuenca A Front Transplant. 2023; 2.
PMID: 37994308 PMC: 10664839. DOI: 10.3389/frtra.2023.1067512.